Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 25;39(9):1494–1503. doi: 10.1093/ndt/gfae021

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 4: — Renal structural changes at weeks 8 and 16 of treatment are correlated with change in ln (ACR) at week 4 of treatment. Relationship between change (delta) in ln (ACR) from week 0 to week 4 of treatment and (A) glomerulosclerosis after week 8 of treatment, (B) podocyte number (WT-1 immunostaining) after week 8 of treatment, (C) glomerulosclerosis after week 16 of treatment. (D) podocyte number (WT-1 immunostaining) after 16 weeks of treatment. (E) Glycocalyx % lectin positive area after 16 weeks of treatment. r = correlation coefficient. Change in ln (ACR) at week 4 is significantly correlated with glomerulosclerosis [P < .0001 (A), P < .01 (C)], podocyte number [P < .01 (B), P < .0001 (D)] and glycocalyx damage [P < .001 (E)].